EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer

Yipeng Zhang, Kaijie Liang, Xiaoyu Zhou, Xin Zhang, Hui Xu, Hongjiu Dai, Xueru Song, Xueyi Yang, Baorui Liu iD, Tao Shi, Jia Wei iD

Cancer Science · 2023

DOI: 10.1111/cas.15828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Yipeng Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Stomach Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, the Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the successful application of chimeric antigen receptor (CAR)‐T cell therapy in hematological malignancies, the treatment efficacy in solid tumors remains unsatisfactory, largely due to the highly immunosuppressive tumor microenvironment and low density of specific tumor antigens. Natural killer group 2 member D (NKG2D) CAR‐T cells have shown promising treatment effects on several cancers such as lymphoma and multiple myeloma. However, the application and efficacy of NKG2D‐CAR‐T cells in gastric cancer (GC) still needs further exploration. This study identified a novel combination immunotherapy strategy with Dickkopf‐1 (DKK1) inhibition and NKG2D‐CAR‐T cells, exerting synergistic and superior antitumor effect in GC. We show that the baseline expression of NKG2D ligands (NKG2DLs) is at low levels in GC tissues from The Cancer Genome Atlas and multiple GC cell lines including NCI‐N87, MGC803, HGC27, MKN45, SGC7901, NUGC4, and AGS. In addition, DKK1 inhibition by WAY‐262611 reverses the suppressive tumor immune microenvironment (TIME) and upregulates NKG2DL expression levels in both GC cell lines and GC tissues from a xenograft NCG mouse model. DKK1 inhibition in GC cells markedly improves the immune‐activating and tumor‐killing ability of NKG2D‐CAR‐T cells as shown by cytotoxicity assays in vitro. Moreover, the combination therapy of NKG2D‐CAR‐T and WAY‐262611 triggers superior antitumor effects in vivo in a xenograft NCG mouse model. In sum, our study reveals the role of DKK1 in remodeling GC TIME and regulating the expression levels of NKG2DLs in GC. We also provide a promising treatment strategy of combining DKK1 inhibition with NKG2D‐CAR‐T cell therapy, which could bring new breakthroughs for GC immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenStomach NeoplasmsHumansMiceAnimalsNK Cell Lectin-Like Receptor Subfamily KCell Line, TumorImmunotherapy, AdoptiveT-LymphocytesTumor MicroenvironmentIntercellular Signaling Peptides and ProteinsNaphthalenesPiperidinesPyrimidines

Stichwörter der Autor:innen

DKK1NKG2D-CAR-Tcombination immunotherapygastric cancertumor microenvironment

Substanzen

Receptors, Chimeric AntigenNK Cell Lectin-Like Receptor Subfamily KIntercellular Signaling Peptides and ProteinsWAY-262611NaphthalenesPiperidinesPyrimidinesDKK1 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Nanjing Kaedi Biotherapeutics Co. Ltd., Nanjing, China.
  • Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, China.

ORCID-Profile: Baorui Liu, Jia Wei

Förderung

  • National Natural Science Foundation of China
  • the Fundamental Research Funds for the Central Universities

Zitieren

APA

Zhang, Y., Liang, K., Zhou, X., Zhang, X., Xu, H., Dai, H., Song, X., Yang, X., Liu, B., Shi, T., & Wei, J. (2023). Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer. Cancer Science. https://doi.org/10.1111/cas.15828

Vancouver

Zhang Y, Liang K, Zhou X, Zhang X, Xu H, Dai H, et al. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer. Cancer Science. 2023. doi:10.1111/cas.15828

BibTeX
@article{Zhang2023,
  author = {Zhang, Yipeng and Liang, Kaijie and Zhou, Xiaoyu and Zhang, Xin and Xu, Hui and Dai, Hongjiu and Song, Xueru and Yang, Xueyi and Liu, Baorui and Shi, Tao and Wei, Jia},
  title = {Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer},
  journal = {Cancer Science},
  year = {2023},
  doi = {10.1111/cas.15828}
}
Kostenlos starten →